Key features and details | |
Cat. No. | MABL-1299 |
Name | Anti-CXCL12 mAbs |
Clone No. | AFD- 30D8 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | BLI, Blocking, crystallization, in vitro, in vivo, ELISA |
Species Reactivity | Rat, Human, Cynomolgus Monkey, Mouse |
Basic Information | |
Specificity | This antibody is specific for CXCL12. In mouse and human, it has been shown to bind CXCL12α, CXCL12β, and CXCL12γ. |
Alternative Name | SDF1; SDF-1; Stromal cell-Derived Factor 1; C-X-C motif chemokine 12; C- X-C motif chemokine ligand 12; IRH; PBSF; SCYB12; TLSF; TPAR1; CXCL12α; CXCL12β; CXCL12γ |
UniProt | |
Immunogen | The original antibody was generated by hyperimmunization of Armenian hamsters with recombinant human CXCL12α. |
Application Notes | The original format of this antibody (Hamster IgG, κ) completely blocked chemotaxis of Jurkat cells elicited by CXCL12α with an average IC50 of approximately 0.5 μg/mL (~3 nmol/L). This antibody successfully and specifically blocked CXCL12α binding to CXCR4 and CXCR7, inhibited CXCL12α- induced Rac1 activation in a dose-dependent manner, and effectively suppressed primary tumor growth in mouse lymphoma and Lewis lung carcinoma models. Additionally, 30D8 showed significant inhibition of lung metastasis in a breast cancer model and reduced choroidal neovascularization in a mouse model. In a collagen-induced arthritis mouse model, 30D8 slowed down disease progression and, in combination with anti-TNF antibody, prevented disease advancement, reducing bone-erosive changes. The humanized version of this antibody (hu30D8) demonstrated binding affinity not only to CXCL12α but also to CXCL12β and CXCL12γ in direct ELISA assays. |
Antibody First Published | Zhong et al. Development and preclinical characterization of a humanized antibody targeting CXCL12 Clin Cancer Res. 2013 Aug 15;19(16):4433-45. doi: 10.1158/1078-0432.CCR-13- 0943. Epub 2013 Jun 28 PMID: 23812669 |
Note on publication | The original publication describes the development and preclinical characterization of a potent humanized antibody, hu30D8, targeting mouse/human CXCL12, demonstrating its efficacy in blocking CXCL12 binding to CXCR4 and CXCR7, inhibiting tumor growth, metastasis, arthritis, and choroidal neovascularization in mouse models, indicating its potential for cancer and inflammation-related disease treatments. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
